Key result
The NHLBI workshop identified key gaps and opportunities in basic, translational, and clinical research focusing on the potential of mitochondria-based therapeutic strategies in heart failure.
Answers are grounded in this paper and cite their sources.
This workshop report outlines a comprehensive roadmap for future research to translate mitochondrial biology into novel therapies for heart failure.
Mitochondria have emerged as a central factor in the pathogenesis and progression of heart failure, and other cardiovascular diseases, as well, but no therapies are available to treat mitochondrial dysfunction. The National Heart, Lung, and Blood Institute convened a group of leading experts in heart failure, cardiovascular diseases, and mitochondria research in August 2018. These experts reviewed the current state of science and identified key gaps and opportunities in basic, translational, and clinical research focusing on the potential of mitochondria-based therapeutic strategies in heart failure. The workshop provided short- and long-term recommendations for moving the field toward clinical strategies for the prevention and treatment of heart failure and cardiovascular diseases by using mitochondria-based approaches.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2019) conducted a review in Heart failure and cardiovascular diseases. Mitochondria-based therapeutic strategies was evaluated. The NHLBI workshop identified key gaps and opportunities in basic, translational, and clinical research focusing on the potential of mitochondria-based therapeutic strategies in heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: